Canonical_Trait
ALK rearrangement/fusion status
Ability to safely receive investigational and SOC regimens
Ability to swallow oral medication
Absence of identifiable primary tumor or nodal disease
Absolute neutrophil count
Actionable mutations
Active infection
Acute disease
Advanced refractory solid tumors
Age
Alkaline phosphatase
Allogeneic transplant
Alpha-fetoprotein level
Amenability to consolidation immunotherapy
Anticoagulant treatment
Anticoagulation treatment
Arterial thrombotic events
Autoimmune disease/disorder
Bevacizumab treatment continuity
Bleeding/Coagulation disorders
Blood pressure control
Body weight
Brain imaging
Brain metastases
CT chest with IV contrast or PET/CT
CYP3A4 inhibitors/inducers
Cardiac conditions
Centrally located primary tumor <2 cm from nodal disease (overlap risk)
Chemotherapy cycles
Chemotherapy timing
Child-Pugh classification
Complete resection
Concurrent anti-cancer therapy
Concurrent antineoplastic therapy
Concurrent clinical trials
Contraception
Creatinine clearance/Renal function
Curative intent eligibility (clinical appropriateness)
Denosumab use
Diabetes
Diagnosis
Disease progression
Disease progression status
Disease recurrence timing
Drug allergy/hypersensitivity
EBV infection
ECOG Performance Status
EGFR mutation status
EGFR/ALK/ROS1/BRAF combined status
Epstein-Barr virus (EBV) infection
Extracapsular extension
Germline sequencing
Gross disease remaining
HBV status
HCC diagnosis
HCV status
HER2 status
HIV status
Hematologic function
Hemoglobin
Hepatic disorder
Hepatitis status (combined)
Histology
Identified primary tumor and at least one nodal metastasis
Imaging timing
Immunostimulatory agents
Immunosuppression
Infection
Informed consent
Inoperability status
Interstitial lung disease/pneumonitis
Investigational study participation
Investigational therapy
Investigator discretion
Investigator judgment
Investigator judgment early termination risk
KRAS mutation
Kaposi sarcoma/MCD in HIV
Lab abnormalities
Life expectancy
Life-threatening non-cancer illness
Live vaccine
Liver function
MDS/AML
MRD status
Maintenance therapy history
Malabsorption syndromes
Measurable disease
Medical/psychiatric conditions
Metastatic disease
Metastatic or locally recurrent gastro-oesophageal cancer
Minimal pleural effusion eligibility
N2 node sampling
NSCLC resection status
Neurological/psychiatric disorders
No evidence of distant metastases (by FDG PET/CT)
Non-healing wounds
Non-malignant pleural effusion status
Nucleoside analog treatment
Organ function
Organ transplant
Other driver oncogenes
Other malignancy
PD-L1 expression/status
PET-CT timing
PET/CT staging
"Pathologically proven non-operable stage IIB or III, node positive NSCLC"
Pericardial effusion
Platelet count
Platinum doublet contraindication
Platinum doublet cycles
Platinum doublet progression
Platinum-based chemotherapy contraindication
Pleural fluid cytology if effusion visible on CT and x-ray
Positive microscopic margins
Post-op chest CT
Post-op recurrence
Pre-op FDG-PET/CT
Pre-op chest CT/MRI
Pre-op imaging coverage
Pre-op mediastinal staging
Pre-surgical plasma sample
Pregnancy/reproductive status
Primary tumor site
Primary tumor size â‰¤7 cm
Prior PARP inhibitor
Prior PD-1/PD-L1 therapy
Prior Stage III therapy
Prior adjuvant/neoadjuvant therapy
Prior anti-TIGIT therapy
Prior anti-VEGF therapy
Prior checkpoint inhibitor therapy
Prior chemoradiation
Prior chemotherapy
Prior immunotherapy
Prior radiotherapy
Prior systemic therapy
Prior targeted therapy
Proteinuria
Psychotropic drug or alcohol abuse
Pulmonary function
ROS1 rearrangement
Radiation dose
Radiation therapy
Re-resection status
Recent biological response modifiers
Recent drug therapy
Recent investigational treatment
Recent radiotherapy
Recent systemic therapy
Recent/Major surgery
Recurrent or refractory NSCLC
Resection type
Residency and ancestry
STK11 mutation
Second-line therapy refusal
Seizure disorder
Separate tumor nodules in same lobe
Serum albumin
Sex
Smoking status
Stage
Steroid use
Study compliance willingness
Surgical margins
Surgical resectability/inoperability/refusal
Systemic disease
TACE eligibility
Thyroid function
Time from progression to randomization
Toxicity
Toxicity from prior therapy
Toxicity recovery
Treatment start feasibility
Tuberculosis
Tumor tissue/sample
Uncontrolled illness
Uncontrolled intercurrent illness
Unresectable/metastatic disease
Vascular aneurysms
Venous thrombotic events
Viral load
Wedge resection
Weight loss
Whole blood transfusion
Wound healing
actionable_driver_oncogenes
actionable_genomic_alterations
actionable_molecular_alterations
adhesive_allergy
adjuvant_progression_timing
adjuvant_therapy
allogeneic_transplant
blood_pressure
body_weight
cerebrovascular_accident
chemotherapy_recovery
clinical_study_participation
compliance
concurrent_anticancer_therapy
concurrent_experimental_therapy
concurrent_investigational_therapy
corneal_disease
ct_scan
curative_intent_therapy
device_operation
diabetes
disease_burden
disease_progression
disease_response
docetaxel_contraindication
early_stage_relapse
enrollment_timing
fdg_pet_ct
fistula
follow_up_accessibility
gi_abnormalities
gi_absorption_condition
gi_disease
hypertension
immunotherapy_contraindication
implantable_devices
institutionalization
intercurrent_illness
interference_condition
investigational_therapy
mds_aml_history
medical_psychiatric_risk
metastatic_progression_timing
molecular_alterations
molecular_status
mrd_eligibility
other_actionable_alterations
pembrolizumab_monotherapy
peripheral_neuropathy
persistent_disease
physician_assigned_therapy
planned_surgery
platinum_cycles
post_platinum_therapy
post_treatment_imaging
preop_imaging
prior_immune_related_ae
prior_mmae_ib6_therapy
prior_parp_inhibitor
prior_topoisomerase_adc
prior_toxicity
prior_transplant
prior_transplantation
psychiatric_condition
qtcf_interval
questionnaire_completion
radiation_dose
radiation_technique
recent_antitumor_therapy
recent_colony_stimulating_factor
recent_pet
recent_radiotherapy
recovery_from_prior_therapy
resection_types
residual_disease_site
second_screen_imaging
smoking_status
surveillance_consent
surveillance_start_timing
swallowing_ability
synchronous_tumors
systemic_therapy_timing
third_space_fluid_retention
treatment_start
tumor_cavitation_vessel_invasion
tumor_size_number
unapproved_surgical_procedures
unresectable_nsclc
unresectable_status
washout_period
wedge_resection
whole_blood_transfusion
wound_healing
